fbpx

RAMP-301 | NCT06072781

The RAMP-301 trial will assess the safety and efficacy of the combination of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment options (ICT) in patients with recurrent Low-grade Serous Ovarian Cancer (LGSOC) who have progressed on a prior platinum-based [...]

RAMP-301 | NCT060727812024-07-19T11:32:01+10:00

EN.10/TAPER | NCT05640999

The primary objective of this study is to estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status.

EN.10/TAPER | NCT056409992024-07-09T16:59:38+10:00

EPOCH | NCT05619913

EPOCH is a Phase II open label international clinical trial, which seeks to improve outcomes in women with tubo-ovarian or uterine carcinosarcoma by providing patients with access to a treatment that offers a greater degree of clinical benefit compared [...]

EPOCH | NCT056199132024-07-09T17:00:21+10:00

PARAGON-II | ACTRN12621000639820

PARAGON-II is a trial investigating whether a combination of two drugs (letrozole with alpelisib or letrozole with ribociclib) is an active treatment for a range of advanced gynaecological cancers that expresses hormone receptors.

PARAGON-II | ACTRN126210006398202024-07-09T17:00:40+10:00

ADELE | ACTRN12621000273886

ADELE is a randomised phase 2 trial testing the effect of ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer.  

ADELE | ACTRN126210002738862024-07-09T17:00:50+10:00

HyNOVA | ACTRN12621000269831

HyNOVA is a randomised study comparing hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer.

HyNOVA | ACTRN126210002698312024-07-09T17:01:27+10:00

IGNITE | ACTRN12619001185156P

IGNITE is testing how effective adavosertib treatment is for patients with relapsed high grade serous or endometrioid ovarian cancer with particular genetic faults, which alter how tumour cells respond to treatment.

IGNITE | ACTRN12619001185156P2024-07-09T17:01:43+10:00
Go to Top